These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38771515)

  • 21. Molecular imaging using positron emission tomography in colorectal cancer.
    Lin M
    Discov Med; 2011 May; 11(60):435-47. PubMed ID: 21616042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.
    Li L; Lin X; Wang L; Ma X; Zeng Z; Liu F; Jia B; Zhu H; Wu A; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3735-3749. PubMed ID: 37382662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective comparative study of contrast-enhanced CT, contrast-enhanced MRI and 18F-FDG PET/CT in the preoperative staging of colorectal cancer patients.
    Guney IB; Teke Z; Kucuker KA; Yalav O
    Ann Ital Chir; 2020; 91():658-667. PubMed ID: 32213686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography.
    Izuishi K; Yamamoto Y; Sano T; Takebayashi R; Nishiyama Y; Mori H; Masaki T; Morishita A; Suzuki Y
    J Gastrointest Surg; 2012 Feb; 16(2):394-400. PubMed ID: 22065316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [18F-fluorodeoxyglucose positron emission tomography in colorectal cancer: value in primary staging and follow-up].
    Jörg L; Heinisch M; Rechberger E; Kurz F; Klug R; Aufschnaiter M; Hammer J; Langsteger W
    Acta Med Austriaca; 2002; 29(5):176-9. PubMed ID: 12506769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
    Ma B; King AD; Leung L; Wang K; Poon A; Ho WM; Mo F; Chan CML; Chan ATC; Wong SCC
    Ann Oncol; 2017 Jul; 28(7):1576-1581. PubMed ID: 28379285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy.
    Takahashi S; Kuroki Y; Nasu K; Nawano S; Konishi M; Nakagohri T; Gotohda N; Saito N; Kinoshita T
    Anticancer Res; 2006; 26(6C):4705-11. PubMed ID: 17214330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer.
    Nomura M; Takahashi H; Haraguchi N; Nishimura J; Hata T; Matsuda C; Ikenaga M; Yamamoto H; Murata K; Doki Y; Mori M; Mizushima T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1219-1226. PubMed ID: 29075856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET-scan in colorectal cancer.
    Lonneux M
    Acta Chir Belg; 2005 Aug; 105(4):333-7. PubMed ID: 16184712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
    Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
    Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
    Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
    Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using 18F-FDG positron emission tomography/computed tomography to judge benign or malignant colorectal hypermetabolic lesions.
    Li W; Fan W
    Chin J Cancer; 2010 Mar; 29(3):306-11. PubMed ID: 20193115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans.
    Monteil J; Mahmoudi N; Leobon S; Roudaut PY; El Badaoui A; Verbeke S; Venat-Bouvet L; Martin J; Le Brun-Ly V; Lavau-Denes S; Maubon A; Bouillet P; Pouquet M; Vandroux JC; Tubiana-Mathieu N
    Anticancer Res; 2009 Jul; 29(7):2563-8. PubMed ID: 19596929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Established, emerging and future roles of PET/CT in the management of colorectal cancer.
    Herbertson RA; Scarsbrook AF; Lee ST; Tebbutt N; Scott AM
    Clin Radiol; 2009 Mar; 64(3):225-37. PubMed ID: 19185652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.